news

Daiichi Sankyo receives approval for the use of Inavir® to prevent influenza

Posted: 23 December 2013 | | No comments yet

Daiichi Sankyo has received approval in Japan to market Inavir® Dry Powder Inhaler 20mg (generic name: Laninamivir Octanoate Hydrate)…

Daiichi Sankyo logo

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo), announced today that it received approval in Japan to market Inavir® Dry Powder Inhaler 20mg (generic name: Laninamivir Octanoate Hydrate) for the prevention of influenza in both adults and children.

Inavir® is a long-acting neuraminidase inhibitor developed by Daiichi Sankyo which is manufactured in Japan. The drug was originally launched in Japan for treatment of influenza A and B in October 2010.

Daiichi Sankyo has great expectations for the additional influenza prevention indication for Inavir®, which will provide an additional option for the public to protect themselves against the influenza virus and allow Daiichi Sankyo to further contribute to the health of society.

Related organisations

Related diseases & conditions